Cidara Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Cidara Therapeutics, Inc. (CDTX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-169.83-22.93-33.58-42.47-72.11-41.09-59.02
Depreciation & Amortization0.230.120.14-1.231.050.380.52
Stock Based Compensation3.913.063.534.014.090.000.00
Change in Working Capital-13.93-3.920.4514.4412.54-3.56-0.40
Change in Accounts Receivable14.28-10.41-0.485.82-11.170.000.00
Change in Inventory6.10-6.100.000.000.000.000.00
Change in Accounts Payable-1.008.89-2.37-1.096.590.000.00
Change in Other Working Capital-11.971.24-3.290.021.910.000.00
Other Operating Activities1.101.240.980.020.0214.490.09
Net Cash from Operating Activities-176.53-22.43-28.47-25.23-54.41-28.53-56.71
Investing Activities
Capital Expenditures-0.13-0.51-0.12-0.04-0.190.04-0.18
Sales/Maturities of Investments0.000.000.000.000.000.0014.48
Net Cash from Investing Activities-0.13-0.51-0.12-0.04-0.19-0.0414.30
Financing Activities
Debt Repayment-0.280.00-2.59-4.44-2.960.000.00
Common Stock Issued337.3825.962.3649.0440.245.296.44
Common Stock Repurchased-0.040.000.000.000.000.000.00
Other Financing Activities-0.040.00-0.720.000.000.0049.51
Net Cash from Financing Activities337.0625.98-0.9544.6037.2814.2756.15
Summary
Net Change in Cash160.403.05-29.5419.32-17.32-14.2913.75
Cash at Beginning of Period35.7832.7362.2742.9560.2774.5660.81
Cash at End of Period196.1835.7832.7362.2742.9560.2774.56
Free Cash Flow-176.66-22.94-28.59-25.27-54.60-28.57-56.88
Supplemental Disclosures
Interest Paid0.000.000.040.230.450.620.58
Income Taxes Paid0.100.800.000.000.000.000.00